BR0206237A - Uso de um composto de carboestiril - Google Patents

Uso de um composto de carboestiril

Info

Publication number
BR0206237A
BR0206237A BR0206237-2A BR0206237A BR0206237A BR 0206237 A BR0206237 A BR 0206237A BR 0206237 A BR0206237 A BR 0206237A BR 0206237 A BR0206237 A BR 0206237A
Authority
BR
Brazil
Prior art keywords
compound
carbon
medicament
salt
carbostyril compound
Prior art date
Application number
BR0206237-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Shaun Jordan
Tetsuro Kikuchi
Katsura Tottori
Tsuyoshi Hirose
Yasufumi Uwahodo
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25087808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0206237(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR0206237A publication Critical patent/BR0206237A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR0206237-2A 2001-01-29 2002-01-29 Uso de um composto de carboestiril BR0206237A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77021001A 2001-01-29 2001-01-29
PCT/JP2002/000626 WO2002060423A2 (en) 2001-01-29 2002-01-29 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists

Publications (1)

Publication Number Publication Date
BR0206237A true BR0206237A (pt) 2003-12-23

Family

ID=25087808

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206237-2A BR0206237A (pt) 2001-01-29 2002-01-29 Uso de um composto de carboestiril

Country Status (19)

Country Link
EP (3) EP1621198B1 (https=)
JP (4) JP4178032B2 (https=)
KR (5) KR100601073B1 (https=)
CN (3) CN1239154C (https=)
AR (4) AR032641A1 (https=)
AT (3) ATE504293T1 (https=)
AU (4) AU2002226752C1 (https=)
BR (1) BR0206237A (https=)
CA (2) CA2429496C (https=)
CY (3) CY1105631T1 (https=)
DE (3) DE60239711D1 (https=)
DK (3) DK1712225T3 (https=)
ES (3) ES2363366T3 (https=)
MX (2) MX344556B (https=)
MY (1) MY129355A (https=)
PH (1) PH12014500937A1 (https=)
PT (3) PT1621198E (https=)
TW (2) TWI331919B (https=)
WO (1) WO2002060423A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
AU2003268026A1 (en) * 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
CN1989968B (zh) * 2002-12-27 2011-05-11 大塚制药株式会社 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂
CN102166359A (zh) * 2003-05-23 2011-08-31 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
ES2646326T3 (es) * 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
TW200848041A (en) * 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JP2009286740A (ja) * 2008-05-30 2009-12-10 Otsuka Pharmaceut Co Ltd アリピプラゾールを含有する逆耐性抑制剤
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
AR090245A1 (es) 2012-03-06 2014-10-29 Otsuka Pharma Co Ltd Preparacion solida oral de liberacion sostenida, metodo de preparacion
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
US4764416A (en) 1986-07-01 1988-08-16 Mitsubishi Denki Kabushiki Kaisha Electric element circuit using oxidation-reduction substances
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
WO1992020655A1 (en) * 1991-05-20 1992-11-26 The Upjohn Company Carboxamido-(1,2n)-carbocyclic-2-aminotetralin derivatives
US5532240A (en) * 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
WO1994009765A1 (en) * 1992-10-23 1994-05-11 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
JP2959615B2 (ja) * 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) * 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
US6110918A (en) * 1996-05-07 2000-08-29 Pfizer Inc Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist
JP4012994B2 (ja) * 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
JP2000516936A (ja) * 1996-08-27 2000-12-19 アメリカン・ホーム・プロダクツ・コーポレイション ドパミンｄ２作動薬としておよび５―ｈｔ１ａリガンドとしての４―アミノエトキシインドール
EP1053235A1 (en) * 1998-02-03 2000-11-22 American Home Products Corporation Oxazole derivatives as serotonin-1a receptor agonists
WO1999052870A1 (en) * 1998-04-13 1999-10-21 American Home Products Corporation 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
JPH11335286A (ja) * 1998-05-25 1999-12-07 Mitsui Chem Inc ドーパミン拮抗薬の効果増強剤
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
EA009780B1 (ru) * 2001-06-19 2008-04-28 Норберт Мюллер Применение ингибиторов cox-2 для лечения шизофрении, аффективных расстройств или осложнений, связанных с тиком
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

Also Published As

Publication number Publication date
HK1061805A1 (en) 2004-10-08
DK1712225T3 (da) 2011-06-20
CN1484524A (zh) 2004-03-24
AU2005201772C1 (en) 2010-06-03
CA2700314C (en) 2012-04-24
TW200522960A (en) 2005-07-16
JP2007297405A (ja) 2007-11-15
ES2286755T3 (es) 2007-12-01
KR20070065425A (ko) 2007-06-22
KR100713607B1 (ko) 2007-05-02
CA2700314A1 (en) 2002-08-08
TWI331919B (en) 2010-10-21
ATE362763T1 (de) 2007-06-15
KR100601073B1 (ko) 2006-07-19
DE60239711D1 (de) 2011-05-19
TWI302832B (en) 2008-11-11
AU2002226752B2 (en) 2005-03-17
DE60210581D1 (en) 2006-05-24
HK1091403A1 (zh) 2007-01-19
CA2429496A1 (en) 2002-08-08
MX344556B (es) 2016-12-20
AU2007201701A1 (en) 2007-05-10
ES2261652T3 (es) 2006-11-16
AR099754A2 (es) 2016-08-17
EP1621198A3 (en) 2006-04-12
AU2002226752C1 (en) 2010-02-18
AR080849A2 (es) 2012-05-09
KR100825705B1 (ko) 2008-04-29
AU2009233591A1 (en) 2009-11-19
JP4178032B2 (ja) 2008-11-12
EP1621198B1 (en) 2007-05-23
JP2011184460A (ja) 2011-09-22
AR032641A1 (es) 2003-11-19
JP4896831B2 (ja) 2012-03-14
PH12014500937A1 (en) 2015-09-21
EP1355639A2 (en) 2003-10-29
JP5683010B2 (ja) 2015-03-11
KR20030065570A (ko) 2003-08-06
EP1712225A1 (en) 2006-10-18
KR100653591B1 (ko) 2006-12-05
DK1355639T3 (da) 2006-08-14
AU2007201701B2 (en) 2010-06-17
PT1355639E (pt) 2006-06-30
AU2005201772A1 (en) 2005-05-19
KR100763288B1 (ko) 2007-10-04
JP2004517937A (ja) 2004-06-17
AR079761A2 (es) 2012-02-15
AU2009233591B2 (en) 2011-10-20
DE60220325D1 (de) 2007-07-05
JP2011225587A (ja) 2011-11-10
DK1621198T3 (da) 2007-09-24
CN1239154C (zh) 2006-02-01
CN100450485C (zh) 2009-01-14
CY1105631T1 (el) 2010-12-22
WO2002060423A3 (en) 2003-04-10
WO2002060423A2 (en) 2002-08-08
ATE504293T1 (de) 2011-04-15
PT1621198E (pt) 2007-06-08
MY129355A (en) 2007-03-30
DE60210581T2 (de) 2007-04-05
EP1355639B1 (en) 2006-04-12
MXPA03006603A (es) 2004-02-12
ES2363366T3 (es) 2011-08-02
CY1108031T1 (el) 2013-09-04
AU2005201772B2 (en) 2007-05-17
DE60220325T2 (de) 2008-01-17
KR20060085260A (ko) 2006-07-26
CA2429496C (en) 2010-10-19
PT1712225E (pt) 2011-04-18
KR20060028485A (ko) 2006-03-29
KR20050107822A (ko) 2005-11-15
ATE322894T1 (de) 2006-04-15
EP1712225B1 (en) 2011-04-06
CN1879624A (zh) 2006-12-20
EP1621198A2 (en) 2006-02-01
CY1111392T1 (el) 2015-08-05
CN1813745A (zh) 2006-08-09

Similar Documents

Publication Publication Date Title
BR0206237A (pt) Uso de um composto de carboestiril
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
BR0312729A (pt) Novos derivados de indol-3-enxofre
BR0312095A (pt) Composto, composição farmacêutica, e, uso de um composto
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BR0311591A (pt) 1-(aminoalquil)-2-sulfonilazindóis como ligandos de 5-hidroxitriptamina-6
BRPI0511504A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
BR0110767A (pt) Derivados de piperidina farmaceuticamente ativos, em particular como moduladores da atividade de receptor de quimiocina
BR0113448A (pt) Composto da fórmula ou um sal ou solvato deste ou um derivado destes fisiologicamente funcional, composição farmacêutica, uso do composto ou de um sal ou solvato deste ou de um derivado destes fisiologicamente funcional, e , métodos para tratar uma condição ou estado de doença mediados pela p38 quinase ou mediados pelas citoquinas, e mediados pela jnk quinase ou mediados pelas citoquinas, e ,para tratar duas ou mais condições ou doenças independentemente mediadas pela atividade da p38 e da jnk quinase
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
BRPI0509761B8 (pt) compostos de quinolinona-carboxamida como agonistas de receptor de 5-ht4, composição farmacêutica, uso dos referidos compostos e seu processo de preparação
BR0314488A (pt) Composto, composição farmacêutica e métodos de tratamento
BR0005915A (pt) Comprimido matriz que possibilita a liberação prolongada de trimetazidina após a administração pela via oral
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
BR0113590A (pt) 7-oxo-piridopirimidinas
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
BRPI0410050A (pt) método de tratamento ou de profilaxia de distúrbios psicóticos, distúrbios de prejuìzo intelectual ou doenças ou condições nos quais a modulação do receptor alfa7-nicotìnico é benéfica, composição farmacêutica, método de tratamento ou de profilaxia de doenças, uso de um composto, composto, e, método de preparação de um composto
BR0013793A (pt) Medicamentos profiláticos e terapêuticos para doenças oftálmicas
BRPI0408295A (pt) uso de um composto
BR0103210A (pt) Derivados de azabicicloalcano e suas utilizações terapêuticas
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico
BR0102940A (pt) Agente para o tratamento de doença de parkinson compreendendo um agente de melhora da função de astrócitos como ingrediente ativo
EA200800071A1 (ru) Производные бензофуранила как ингибиторы 5-нт6-рецептора

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]